Participated · Series A · Jan 2024

Motif Neurotech is developing the DOT microstimulator, a miniature wireless, battery-free brain pacemaker intended to precisely stimulate neural circuits to treat mental health disorders. The company’s initial clinical focus is treatment-resistant depression (TRD). The DOT device is designed for implantation in an approximately 20-minute outpatient procedure and has capability for at-home therapy. The implant is enabled by wireless magnetoelectric power transfer technology developed at Rice University and was founded by Rice faculty Jacob Robinson and Kaiyuan Yang along with physicians Sunil Sheth and Sameer Sheth. Jacob Robinson serves as CEO and Founder. Motif plans to use recent financing to advance the device into a clinical study for patients with TRD.

Participated · Seed · Jan 2024

TARA Mind develops a clinician-guided, data-driven collaborative care platform to deliver ketamine-assisted therapy (KAT) and other emerging mental health treatments as an employer-covered benefit. The company focuses on individuals with treatment-resistant mental health disorders and aims to integrate personalized, evidence-based care into self-funded employer benefit plans. TARA Mind maintains a structured real-world evidence dataset to support outcomes and decision-making and emphasizes measurable ROI for employers via reduced medical costs, lower absenteeism, and improved productivity. The firm positions itself as a first mover in the employer benefit space for psychedelic-assisted therapies and seeks to expand affordable access nationwide. Founded in 2022 by Marcus Capone with involvement from Red Cell Partners (Grant Verstandig and Dr. Yisroel Brumer), TARA Mind is organized as a public benefit corporation and is scaling its provider network and employer partnerships. The company recently completed a seed financing round to support that expansion. TARA Mind, founded in 2022, is a Public Benefit Corporation emerging from stealth to expand safe, affordable, and effective access to psychedelic-assisted therapy (PAT). The company has built a network of vetted PAT providers across the US and abroad and is developing proprietary digital measurement-based care tools to ensure safety, optimize outcomes, and enable data-driven, value-based reimbursement. It has codified The TARA Mind Way™ and PTIM™, a clinician-guided framework of Preparation, Treatment, Integration, and Monitoring, to guarantee wraparound services and standardize care. TARA Mind is working with early-adopter employers to add its provider network as a supplemental benefit to existing health plans to reduce equity barriers and drive employer ROI. The company has convened medical advisors from institutions including Harvard, Stanford, and Mount Sinai to help define standards of care. Red Cell Partners announced $3 million in pre-seed funding to fuel the company’s mission and product development.

Participated · Seed · Nov 2021

Wavepaths builds on scientific research showing the critical role of music in psychedelic therapy, offering clinicians an AI-powered system that generates personalized, adaptive soundscapes in real time. Practitioners can seamlessly shift emotional atmospheres, depth, activation levels and instrumentation, drawing on compositions from artists such as Jon Hopkins, Greg Haines, Robert Rich and Christina Vantzou. Founded in 2019 by Dr. Mendel Kaelen and Anna Rickman, the company partners with research institutions, universities and psychedelic-therapy providers to study and optimize therapeutic outcomes. The product is currently in closed beta, is used in more than 29 countries and has a wait-list exceeding 5,000 practitioners ahead of a planned public launch later this year. Fresh capital will be deployed to refine the platform’s personalization and music-generation algorithms, scale infrastructure and add features for a broader range of healthcare practices.